Psoriatic Immune Response to Tildrakizumab

Status Recruiting

Clinical Trial Summary

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.

Clinical Trial Description

This is a one-arm, open-label study to examine the effect of Tildrakizumab on cutaneous and blood immune cells of psoriatic patients. Ten subjects with moderate to severe psoriasis will be enrolled. Biopsy and blood samples will be collected before and during treatment and undergo molecular profiling to assess for tildrakizumab-corrected signatures. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05390515
Study type	Interventional
Source	University of California, San Francisco
Contact	Raymond Cho, MD, PhD
Phone	415-575-0524
Email	rashes@ucsf.edu
Status	Recruiting
Phase	Phase 4
Start date	September 1, 2022
Completion date	September 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03669757` - Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis	Phase 1
Completed	`NCT03614078` - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis	Phase 2
Completed	`NCT03584360` - Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin	Phase 2
Recruiting	`NCT04994951` - Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoriasis Vulgaris of Blood-heat Syndrome.	Phase 2
Completed	`NCT02888236` - LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris	Phase 2
Completed	`NCT02533973` - Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population	Phase 4
Completed	`NCT02193815` - A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis	Phase 1
Completed	`NCT01946386` - A Vasoconstriction Study With LEO 90100	Phase 1
Completed	`NCT02004847` - Blue Light for Treating Psoriasis Vulgaris	N/A
Recruiting	`NCT01443338` - Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2	Phase 4
Completed	`NCT01188928` - LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)	Phase 3
Completed	`NCT00764751` - Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris	Phase 2
Completed	`NCT00236171` - Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test	N/A
Completed	`NCT04541329` - Predicting Inflammatory Skin Disease Response to IL-23 Blockade	Phase 4
Completed	`NCT06064084` - Incretin Effect in Patients With Psoriasis and Controls
Not yet recruiting	`NCT06398106` - Proactive TDM Versus Standard Use of Biologics in Psoriasis	Phase 4
Recruiting	`NCT05892640` - Low-Salt Diet Effect on Th17-Mediated Inflammation and Vascular Reactivity in Psoriasis	N/A
Recruiting	`NCT04950218` - The Psoriasis Echo Study
Completed	`NCT05184348` - Plexin B2 Gene Expression and Polymorphisms in Psoriasis	Phase 1
Recruiting	`NCT04394936` - An Explorative Psoriasis Biomarker Study	N/A